Shares of Loxo Oncology (NASDAQ: LOXO) soared nearly 59% today after the clinical-stage biopharma announced interim data for three clinical trials over the weekend at the American Society of Clinical Oncology’s annual meeting, which is more commonly referred to as ASCO. The company’s lead drug candidate, larotrectinib, demonstrated a 76% objective response rate in adult and pediatric patients with tumors that have specific genetic markers.